FSP1 is a predictive biomarker of osteosarcoma cells' susceptibility to ferroptotic cell death and a potential therapeutic target

Elzbieta Panczyszyn,Valentina Saverio,Romina Monzani,Mara Gagliardi,Jelena Petrovic,Jasmina Stojkovska,Licio Collavin,Marco Corazzari

DOI: https://doi.org/10.1038/s41420-024-01854-2

2024-02-18

Cell Death Discovery

Abstract:Human osteosarcoma (OS) is a relatively rare malignancy preferentially affecting long body bones which prognosis is often poor also due to the lack of effective therapies. Clinical management of this cancer basically relies on surgical removal of primary tumor coupled with radio/chemotherapy. Unfortunately, most osteosarcoma cells are resistant to conventional therapy, with the undergoing epithelial-mesenchymal transition (EMT) giving rise to gene expression reprogramming, thus increasing cancer cell invasiveness and metastatic potential. Alternative clinical approaches are thus urgently needed. In this context, the recently described ferroptotic cell death represents an attractive new strategy to efficiently kill cancer cells, since most chemoresistant and mesenchymal-shaped tumors display high susceptibility to pro-ferroptotic compounds. However, cancer cells have also evolved anti-ferroptotic strategies, which somehow sustain their survival upon ferroptosis induction. Indeed, here we show that osteosarcoma cell lines display heterogeneous sensitivity to ferroptosis execution, correlating with the mesenchymal phenotype, which is consistently affected by the expression of the well-known anti-ferroptotic factor ferroptosis suppressor protein 1 (FSP1). Interestingly, inhibiting the activity or expression of FSP1 restores cancer cell sensitivity to ferroptosis. Moreover, we also found that: i) AKRs might also contribute to resistance; ii) NRF2 enhances FSP1 expression upon ferroptosis induction; while iii) p53 contributes to the regulation of FSP1 basal expression in OS cells.

cell biology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the sensitivity of ferroptosis in osteosarcoma (OS) cells and its mechanism, especially the role of ferroptosis suppressor protein 1 (FSP1) in this process. Specifically:

1. **Heterogeneity of ferroptosis sensitivity**: The study found that there are significant differences in the sensitivity of different osteosarcoma cell lines to ferroptosis. This difference is related to the mesenchymal phenotype of the cells, and the expression level of FSP1 is a key factor affecting this sensitivity.

2. **FSP1 as a predictive marker**: The expression of FSP1 can be used as a biomarker to predict the sensitivity of osteosarcoma cells to ferroptosis. By inhibiting the activity or expression of FSP1, the sensitivity of osteosarcoma cells to ferroptosis can be restored, thus providing a new target for treatment.

3. **Molecular mechanism**: The study further explored the regulatory mechanism of FSP1 expression. The results showed that NRF2 enhances the expression of FSP1 during ferroptosis induction, while p53 is involved in the regulation of basal FSP1 expression.

4. **Other anti - ferroptosis mechanisms**: The study also found that aldose - ketose reductases (AKRs) may play a certain role in the ferroptosis resistance of osteosarcoma cells, but their role is relatively small. In addition, the GCH1/BH4 axis does not seem to be involved in the regulation of the sensitivity of osteosarcoma cells to ferroptosis.

In summary, this paper aims to provide a theoretical basis for the development of new osteosarcoma treatment methods by revealing the role of FSP1 in the ferroptosis sensitivity of osteosarcoma cells and its regulatory mechanism.